节点文献

伊班膦酸钠的临床研究进展

Recent advance in clinical trials of ibandronate monosodium

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 任雷鸣; 朱忠宁; 黄海英; 姜少灏; 袁志芳;

【Author】 REN Lei-ming 1,ZHU Zhong-ning 1,HUANG Hai-ying 1,JIANG Shao-hao 2,YUAN Zhi-fang 1 (1.School of Pharmacy, Hebei Medical University, Shijiazhuang HEBEI 050017,China; 2. Company of Science and Technology, Hebei Medical University, Shijiazhuang HEBEI

【机构】 河北医科大学药学院; 河北医科大学科技总公司; 河北医科大学药学院 河北石家庄050017; 河北石家庄050017; 河北石家庄050017;

【摘要】 伊班膦酸钠属第 3代二膦酸盐类药物 ,是迄今为止本类药物中抑制骨重吸收能力最强、毒性最低的药物。本文综述了伊班膦酸钠用于治疗癌症骨转移或肿瘤引发的高钙血症的临床资料以及伊班膦酸钠的临床药动学资料 ,并对该药的临床安全性进行了评价。此外 ,国外正在进行伊班膦酸钠治疗绝经后骨质疏松症和变形性骨炎的临床试验 ,获得良好效果

【Abstract】 Ibandronate is a newly developed third generation bisphosphonate with the highest potency, relative to other members of its class, in inhibiting bone resorption, and with much higher advantage with regard to the tolerability in clinical study. The authors reviewed the treatment with ibandronate of cancer bone-transffer or tumor-induced hypercalcaemia, and the clinical pharmacokinetic profiles and tolerability of ibandronate. The clinical safety of the drug has been evaluated too. Ibandronate has also been used with great success in late phase clinical trials for the treatment of postmenopausal women with osteoporosis, and for the treatment of Paget’s disease.

【基金】 国家自然科学基金资助项目 (H 39840 0 2 7)
  • 【文献出处】 中国新药与临床杂志 ,Chinese Journal of New Drugs and Clinical Remedies , 编辑部邮箱 ,2002年12期
  • 【分类号】R969
  • 【被引频次】10
  • 【下载频次】330
节点文献中: 

本文链接的文献网络图示:

本文的引文网络